Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - topiramate - tablets - topiramate 200 mg - topiramate - topiramate - in adjunctive therapy of adults and children (from 2 years) with partial seizures and generalized tonic-clonic seizures. in adjunctive therapy of seizures with lennox-gastaut syndrome in adults and children. topitim is indicated as monotherapy in patients with newly diagnosed epilepsy in children aged 7 years and above or for conversion to monotherapy in patients with epilepsy. topitrim is indicated in adults for the prevention of migraines. the use of topitrim in the acute treatment of migraine has not been studied.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - levetiracetam - film coated tablets - levetiracetam 250 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - levetiracetam - film coated tablets - levetiracetam 500 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - levetiracetam - film coated tablets - levetiracetam 1000 mg - levetiracetam - levetiracetam - - levetrim is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - levetrim is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. - levetrim is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in patient from 16 years of age with newly diagnosed epilepsy. - levetrim is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - levetiracetam - solution (oral) - levetiracetam 100 mg/ml - levetiracetam - levetiracetam - levetrim solution is indicated as:- monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. - adjunctive therapy:in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - theophylline anhydrous - tablets slow release - theophylline anhydrous 100 mg - theophylline - theophylline - long acting bronchodilator in the symptomatic relief and/or prevention of asthma and reversible bronchospasm associated with chronic bronchitis and emphysema

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - theophylline anhydrous - tablets slow release - theophylline anhydrous 200 mg - theophylline - theophylline - long acting bronchodilator in the symptomatic relief and/or prevention of asthma and reversible bronchospasm associated with chronic bronchitis and emphysema

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - theophylline anhydrous - tablets slow release - theophylline anhydrous 300 mg - theophylline - theophylline - long acting bronchodilator in the symptomatic relief and/or prevention of asthma and reversible bronchospasm associated with chronic bronchitis and emphysema

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - cetirizine dihydrochloride - tablets - cetirizine dihydrochloride 10 mg - cetirizine - cetirizine - antihistaminic drug for the treatment of allergies. for the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria in children aged 6 years and over and adults.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - cabergoline - tablets - cabergoline 0.5 mg - dopa and dopa derivatives - treatment of hyperprolactinemic disorders.cabotrim is indicated for the treatment of dysfunctions associated with hyperprolactinemia, including amenorrhea, oligomenorrhea, anovulation and galactorrhea. cabotrim is indicated in patients with prolactin-secreting pituitary adenomas (micro-and macroprolactinomas), idiopathic hyperprolactinemia, or empty sella syndrome with associated hyperprolactinemia. inhibition and supression of lactation .